Dusa Pharmaceuticals (DUSA) reports preliminary results of Phase II clinical trials investigating the use of the Levulan Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment — after incubating for one, two or three hours — resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs